149 results about "Azacyclobutane" patented technology

The present invention features a multi-layer ink-jet recording medium, suitable for recording images with dye and pigmented inks and thereby providing light-emitting, reflective, glossy, metallic-looking or holographic images, comprising a substrate coated with at least two layers comprising: (a) a first transparent ink-receptive layer comprising a polymeric binder and a cross-linker and optionally having a plasticizer and pigment particles such as alumina and silica coated over the substrate, wherein the cross-linker comprises and azetidinium polymer or a salt thereof, and/or a polyfunctinal aziridine or a salt thereof or a polyfunctional oxazoline or a salt thereof; and (b) a second ink-receptive layer comprising an opaque or semi-opaque coating composition, wherein the opaque or semi-opaque coating composition is capable of accepting a printed image and thereby becoming semi transparent or clearly transparent from application of ink-jet printing ink or similar inks, while presenting a light-emitting, reflective, glossy, metallic-looking or holographic image of high clarity and quality, wherein said first layer is located between said second layer and the substrate in said recording medium and the first and second layers are chemically coupled.

Improved CO₂ sorbents comprised of a mesoporous silica functionalized with a polyamine are obtained by the in-situ polymerization of azetidine. Also included herein are processes utilizing the improved CO₂ sorbents wherein CO₂ is chemisorbed onto the polyamine portion of the sorbent and the process is thermally reversible.

A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R 1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc, R2, R3, R4 and R5 may be the same or different and each represents hydrogen or fluorine; and R6 represents hydrogen or fluorine.

Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.

The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R¹, R², R³, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

An aqueous blend of an azetidinium functionalized polymer and a polymer having quaternary amine groups is disclosed for use as aqueous pretreatment for substrates such as textiles and garments that are going to be digitally printed. The pretreatment may further comprise wetting agents, surfactants, and preservatives. The pretreatment may be dry or wet immediately prior to digital printing and may be heat treated to bond the pretreatment to the substrate and/or the subsequent print ink.

This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof.

The invention relates, in general, to an improved process for the preparation of the compounds (3R,4S)-4-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one and (3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]-4-(4-hydroxyphenyl)-azetidin-2-one, which are key intermediates for the synthesis of ezetimibe, as well as the use of these intermediates for the preparation of ezetimibe.

The invention discloses a synthesis method of cobimetinib. The method comprises the following steps: respectively carrying out salt forming reaction and bromination reaction on (R)-N-Boc-2-piperidinecarboxylic acid, silver nitrate (or mercuric oxide) and bromine water successively; reacting obtained (R)-N-Boc-2-bromopiperidine and a magnesium rod at first to generate a Grignard reagent, and then carrying out Grignard reaction on the (R)-N-Boc-2-bromopiperidine and 1-carbobenzoxy azetidine-3-one; carrying out deamination protection reaction on obtained 1-carbobenzoxy-3-hydroxy-3-[(2S)-N-Boc-2-piperidyl]-azetidine; carrying out amidation on obtained 3-hydroxy-3-[(2S)-N-Boc-2-piperidyl]-azetidine and 2,3,4-trifluorobenzoyl chloride; carrying out substitution reaction on obtained [2,3,4-trifluorophenyl] [3-hydroxy-3-(2S)-N-Boc-2-piperidyl-1-azetidinyl] ketone and 2-chloro-4-iodoaniline, and finally carrying out deamination protection reaction to obtain the cobimetinib. The method is reasonable and simple in process route, simple to operate and relatively low in cost, is an environmentally friendly method, and is suitable for industrial production.

The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

The disclosure provides strengthened products, including strengthened fibrous composite products and methods for making and using same and strengthened particulates, such as particulate fertilizer products, and methods for making and using same. The fibrous composite product can include a plurality of fibers and an at least partially cured strengthening resin. The fertilizer composition can include a particulate core that can include a plant nutrient, at least one coating layer of the strengthening resin, and at least one coating layer of a water insoluble material. The strengthening resin can include one or more aldehyde-based resins and one or more crosslinked resins. The crosslinked resin can include one or more polyamines at least partially crosslinked by one or more symmetric crosslinks and can include one or more azetidinium functional groups.

The invention discloses a preparation method for Ezetimibe. The preparation method comprises the following steps: adding (3R, 4S)-4-[4-(benzyloxy) phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxo propyl] azacyclobutane-2-one (RM1 for short) into a borane/dimethylsulfide reaction system, and then adding an oxidant to react to generate an Ezetimibe intermediate; and carrying out hydrogenation reduction on the Ezetimibe intermediate to obtain Ezetimibe with a structural formula III. According to the preparation method, in the preparation process of the Ezetimibe intermediate, RM1 is taken as a raw material, dichloromethane is taken as a raw material solvent and (R)-MeCBS/methylbenzene solution is taken as a reaction catalyst, so that the reaction can be accelerated; the yield of the Ezetimibe intermediate can be improved; in the preparation method of Ezetimibe, methanol is taken as a solvent, 10% Pd/C is taken as a reactant, so that low-temperature reaction is carried out; meanwhile, air oxidation reaction is prevented so as to further improve the yield of Ezetimibe.

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows:

wherein R¹, W and

are defined herein.